OnCoCross Co Ltd

OnCoCross maintains a strong liquidity position with KRW 10,808,834,910 in cash and equivalents, representing 64.5% of total assets, and a current ratio of 24.47, well above the industry median of 2.3. The company's price-to-book ratio of 5.72 suggests a premium valuation relative to its tangible book value, while the price-to-tangible-book ratio is identical at 5.72, indicating no intangible asset discounting. Profitability metrics are negative, with a return on equity of -33.35% and return on assets of -32.05%, both significantly below the industry median of 12.5% and 10.2%, respectively. The company reported a net loss of KRW 5,369,587,680 and an operating loss of KRW 5,716,983,610, reflecting the high R&D costs typical in the biotechnology sector. The company's revenue is concentrated in a single business segment focused on AI-driven drug development, with no disclosed geographic diversification. This concentration increases exposure to regulatory and clinical trial risks, particularly in the Korean market where the company is based. Growth trajectory is constrained by the current financial performance, with no disclosed revenue growth in the latest period. The company's forward-looking outlook does not include specific revenue targets, but the high R&D investment and early-stage pipeline suggest long-term growth potential if clinical milestones are achieved. Risk factors include the absence of immediate liquidity or dilution flags, with a low risk score for both. However, the company's high R&D spending and lack of commercialized products increase the risk of future dilution if additional capital is required. No dilution sources were identified in recent filings. Recent events include the continued development of its AI-based drug discovery platform, with no significant regulatory or legal issues disclosed in the latest filings. The company remains focused on expanding its pipeline for rare diseases and oncology.